NMRA is trading about 5.9% up now at $1.72, bouncing from recent weakness after June’s Phase 3 KOASTAL trial failure and workforce reduction, which triggered a nearly 50% stock drop and multiple shareholder investigations. With no new company-specific announcements today and major U.S. indices modestly higher, the move appears to be a technical rebound alongside improving broader market sentiment rather than a reaction to fresh news.